IMR Press / RCM / Volume 7 / Issue S4 / pii/1561344068242-729763998

Reviews in Cardiovascular Medicine (RCM) is published by IMR Press from Volume 19 Issue 1 (2018). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with MedReviews, LLC.

Open Access Review
Effects of GP IIb/IIIa Inhibitors on Vascular Inflammation, Coronary Microcirculation, and Platelet Function
Show Less
1 The Heart Center of Greater Cincinnati and The Lindner Center at The Christ Hospital, Cincinnati, OH, The Ohio State University Department of Medicine and Division of Cardiology, Columbus, OH
Rev. Cardiovasc. Med. 2006, 7(S4), 3–11;
Published: 20 August 2006
Abstract
The platelet glycoprotein (GP) IIb/IIIa inhibitors differ markedly in their pharmacokinetics, pharmacodynamics, and differential receptor affinities. Abciximab and the small-molecule GP IIb/IIIa inhibitors (eptifibatide, tirofiban) have separate, distinct binding sites on the GP IIb/IIIa receptor complex. The affinity of abciximab for the platelet GP IIb/IIIa integrin receptor, together with non-platelet-receptor mediated effects achieved through its affinity for the αVβ3 and CD11b/18 receptors, most likely contribute to the clinical benefit associated with the use of abciximab as adjunctive pharmacotherapy during primary percutaneous coronary intervention for the treatment of ST-elevation acute myocardial infarction.
Keywords
GP IIb/IIIa inhibitors
Abciximab
Percutaneous coronary intervention
Platelet aggregation
Coronary microvascular function
Vascular inflammation
Share
Back to top